| Japanese |
|---|
| Title | 新しい心筋血流イメージング剤99mTc-PPN1011の安全性と臨床的有用性の検討 - 多施設による第II相臨床試験報告 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 佐々木康人*, 西村恒彦**, 久保敦司***, 西川潤一*, 分校久志****, 玉木長良*****, 大嶽達* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京大学医学部放射線科, **大阪大学医学部トレーサ情報解析(核医学), ***慶應義塾大学医学部放射線科, ****金沢大学医学部核医学科, *****京都大学医学部核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 30 |
|---|
| Number | 1 |
|---|
| Page | 25-40 |
|---|
| Year/Month | 1993/1 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」虚血性心疾患患者52例を対象に, 新しい心筋血流イメージング剤99mTc-PPN1011を安静時および運動負荷時の2回, 同日ないし1日以上の間隔をあけて静注し, 安全性および至適投与量・撮像方法について検討するとともに, 臨床上の有用性について評価した, 投与した全例で本剤に起因すると思われる副作用は認められず, 臨床上本剤の安全性に問題はないと考えられた. 1回あたり185MBq以上の投与量で, 投与後10分以降3時間まで良好な画質の像が得られた. 安静試験と運動負荷試験は, 同日でも, 1日以上間隔をあけて行っても, さらにどちらを先に行ってもその有効性に有意な差は認められず, いずれも診断上有効な情報が得られた. 同一症例で201Tl心筋シンチグラフィと比較したところ, シンチグラム所見は安静像で76.2%(337/442セグメント), 負荷像で74.2%(328/442セグメント)の一致をみた. 以上の成績を総合的に評価した結果, 本剤は, 心筋血流イメージング剤として有用であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Myocardial perfusion, 99mTc-PPN1011, Phase II Clinical Trial. 201Tl. |
|---|
| English |
|---|
| Title | Evaluation of the Safety and Clinical Usefulness of a New Myocardial Imaging Agent, 99mTc-PPN1011 - Multicenter Phase II Clinical Trial Report - |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Yasuhito SASAKI*, Tsunehiko NISHIMURA**, Atsushi KUBO***, Junichi NISHIKAWA*, Hisashi BUNKO****, Nagara TAMAKI*****, Tohru OHTAKE* |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, Faculty of Medicine, University of Tokyo, **Department of Tracer Analysis, School of Medicine, Osaka University, ***Department of Radiology, School of Medicine, Keio University, ****Department of Nuclear Medicine, School of Medicine, Kanazawa University, *****Department of Nuclear Medicine, Faculty of Medicine, Kyoto University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 30 |
|---|
| Number | 1 |
|---|
| Page | 25-40 |
|---|
| Year/Month | 1993/1 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]A new myocardial perfusion imaging agent, 99mTc-1, 2-bis[bis(2-ethoxyethyl phosphino]ethane (99mTc-PPN1011) was administered to 52 patients with various heart diseases each at rest and peak exercise on different days (Method A) and on the same day (Method B). The safety, optimal dosage, imaging procedures and the clinical usefulness were evaluated. No drug related adverse reactions were found. Image quality was considered adequate for diagnosis with as little as 185 MBq per injection, though the optimal dose range was 370-740 MBq. SPECT images were obtainable as early as 10 min, also until 3 hours after injection. There were no significant differences in clinical efficacy between method A and B, as well as sequential tests at rest and exercise. 99mTc-PPN1011 and 201Tl images in the same patient were compared segment by segment. Image quality of 99mTc-PPN1011 was significantly superior to that of 201Tl. Analysis of images indicated that both agent were similar in diagnostic efficacy. It was concluded that 99mTc-PPN1011 is useful for myocardial perfusion imaging. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Myocardial perfusion, 99mTc-PPN1011, Phase II Clinical Trial. 201Tl. |
|---|